2018
DOI: 10.32383/farmpol/118683
|View full text |Cite
|
Sign up to set email alerts
|

Omentin – a novel biomarker in medicine? (Part 1)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 35 publications
0
1
0
Order By: Relevance
“…It occurs in two isoforms: omentin-1 (INTL1), detected in the blood, and omentin-2 (INTL2), detected in the intestinal lumen. Reduced blood levels of omentin-1 are thought to be associated with insulin resistance, the development of type 2 diabetes, obesity and metabolic syndrome [110]. Omentin-1 has been shown to play a key role in cell tumourigenesis and differentiation, as well as accelerating apoptosis in cancer cells [111].…”
Section: Omentinmentioning
confidence: 99%
“…It occurs in two isoforms: omentin-1 (INTL1), detected in the blood, and omentin-2 (INTL2), detected in the intestinal lumen. Reduced blood levels of omentin-1 are thought to be associated with insulin resistance, the development of type 2 diabetes, obesity and metabolic syndrome [110]. Omentin-1 has been shown to play a key role in cell tumourigenesis and differentiation, as well as accelerating apoptosis in cancer cells [111].…”
Section: Omentinmentioning
confidence: 99%